Ataraxis
Total Raised
$24.4MInvestors Count
13Funding, Valuation & Revenue
3 Fundings
Ataraxis has raised $24.4M over 3 rounds.
Ataraxis's latest funding round was a Series A for $20.4M on January 3, 2025.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
1/3/2025 | Series A | $20.4M | AIX Ventures, Bertelsmann, Floating Point, Founders Fund, Giant Ventures, Mario Schlosser, Obvious Ventures, Peter Thiel, Ryan Fukushima, Thiel Bio, and Undisclosed Angel Investors | 4 | ||
6/1/2023 | Seed VC | |||||
Other Investors |
Date | 1/3/2025 | 6/1/2023 | |
|---|---|---|---|
Round | Series A | Seed VC | Other Investors |
Amount | $20.4M | ||
Investors | AIX Ventures, Bertelsmann, Floating Point, Founders Fund, Giant Ventures, Mario Schlosser, Obvious Ventures, Peter Thiel, Ryan Fukushima, Thiel Bio, and Undisclosed Angel Investors | ||
Valuation | |||
Revenue | |||
Sources | 4 |
Ataraxis Investors
13 Investors
Ataraxis has 13 investors. Giant Ventures invested in Ataraxis's Series A funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
6/1/2023 | 1/3/2025 | 2 Seed VC, Series A (2025) | Venture Capital | United Kingdom | ||
6/1/2023 | 1/3/2025 | 2 Seed VC, Series A (2025) | Venture Capital | California | ||
1/3/2025 | 1/3/2025 | 1 Series A | Venture Capital | California | ||
Angel Investor (Individual) | California | |||||
Corporation | Germany |
First funding | 6/1/2023 | 6/1/2023 | 1/3/2025 | ||
|---|---|---|---|---|---|
Last Funding | 1/3/2025 | 1/3/2025 | 1/3/2025 | ||
Investor | |||||
Rounds | 2 Seed VC, Series A (2025) | 2 Seed VC, Series A (2025) | 1 Series A | ||
Board Seats | |||||
Type | Venture Capital | Venture Capital | Venture Capital | Angel Investor (Individual) | Corporation |
Location | United Kingdom | California | California | California | Germany |
Compare Ataraxis to Competitors
Stratipath specializes in AI-based precision diagnostics within the healthcare sector, focusing on cancer treatment decision support. The company offers cloud-based SaaS solutions that leverage deep learning technologies to provide risk profiling of tumors, particularly for breast cancer. Stratipath's services are utilized by healthcare providers, including oncology clinics and pathology labs, to enhance the diagnostic process. It is based in Sweden.
Merative is a technology, data, and analytics company focused on the healthcare and government social services sectors. The company offers a range of services including clinical decision support, clinical data management, medical imaging solutions, healthcare analytics, and real-world evidence studies. Merative's solutions serve healthcare providers, health plans, life sciences, and government agencies. Merative was formerly known as IBM - Watson Health. It was founded in 2022 and is based in Ann Arbor, Michigan.
Turbine specializes in oncology drug discovery through its cell simulation platform within the biopharmaceutical sector. The company offers services such as target selection, Antibody-drug conjugates (ADC) payload matching, clinical positioning, and Demand-Driven Research Initiative (DDRi)-related services, focused on improving drug discovery and development. Turbine's platform provides data science insights to identify and validate novel targets and treatments. It was founded in 2016 and is based in Budapest, Hungary.
Agendia is a precision oncology company specializing in genomic profiling for early stage breast cancer. The company offers two main genomic tests, MammaPrint and BluePrint, which provide information to assist in identifying treatment options for breast cancer patients. These tests aim to help in pre- and post-operative treatment decisions by assessing the risk of cancer recurrence and the biology of the tumor. It was founded in 2003 and is based in Irvine, California.
Digistain specializes in breast cancer biomarker analytics within the healthcare technology sector. The company provides a solution that transforms traditional biomarker analysis into a quicker and more affordable process, offering clinicians information for breast cancer recurrence risk profiling. Digistain's technology serves the healthcare sector, integrating with existing clinical workflows to assist in decision-making in cancer treatment. It was founded in 2020 and is based in London, England.
Qualisure Diagnostics Inc. specializes in molecular diagnostics within the healthcare sector, focusing on cancer care. The company develops tests that aim to improve diagnostic accuracy and facilitate tailored cancer treatments. Qualisure's products are designed to support oncologists in treatment decision-making and to contribute to precision medicine initiatives. It was founded in 2017 and is based in Calgary, Alberta.
Loading...